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A B S T R A C T
Background: The aim of this study was to describe incidence patterns of lymphoid neoplasms in the Girona
province (Spain) (1996–2015), and to predict the number of cases in Spain during 2020.
Methods: Data were extracted from the Girona cancer registry. Incident cases were classified using the ICD-O-3,
third revision, and grouped according to the WHO 2008 classification scheme. Age-adjusted incidence rates to
the European standard population (ASRE) were estimated and incidence trends were modeled using Joinpoint.
Results: 4367 lymphoid neoplasms were diagnosed in the Girona province. The ASRE for overall lymphoma was
37.1 (95% CI: 36.0; 38.2), with a marked male predominance in almost all subtypes. During 1996–2015, in-
cidence trends remained stable for broader lymphoma categories. According to our predictions, 17,950 new
cases of LNs will be diagnosed in Spain in 2020.
Conclusions: This ‘real-world’ data will provide valuable information to better inform etiological hypotheses and
plan future health-care services.
1. Introduction
Lymphoid neoplasms (LNs) are a heterogeneous group of hemato-
logical malignancies presenting diverse etiology, presentation and
outcomes [1]. Changing classification schemes [i.e. the Working For-
mulation (WF-1982), the Revised European-American Lymphoma
(REAL, 1994) and the World Health Organization (WHO, 2001, 2008
and 2016) classifications] and scarcity of subtype-specific epidemiolo-
gical data hamper international comparisons. The aim of this study was
to describe incidence patterns of LNs in the Girona province (Spain)
(1996–2015) according to the WHO 2008 classification, and to predict
the number of LNs in Spain during 2020.
2. Material and methods
Data were extracted from the population-based Girona cancer reg-
istry, covering a population of 738,976 inhabitants in 2015. Incident
cases were registered using the International Classification of Diseases
for Oncology, third edition (ICD-O-3) and grouped according to the
WHO 2008 classification scheme. Age-adjusted incidence rates to the
European standard population (ASRE) were estimated and Joinpoint
regression modeling was used to examine temporal trends in age-
standardized rates. Sex- and age-specific projections of cases in Spain in
2020 were estimated, based on the National Statistics Institute of Spain
projections of population.
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3. Results
4367 LNs incident cases (59.7% men) were diagnosed in the Girona
province. Among them, 364 (8.3%) were Hodgkin-lymphoma, 210
(4.8%) precursor lymphoid neoplasms, 3413 (78.2%) mature B-cell
neoplasms, 263 (6.0%) mature T-cell and NK-cell neoplasms, and 117
(2.7%) lymphoid neoplasms not otherwise specified (NOS). Detailed
information can be found in Table 1. In brief, the median age at diag-
nosis ranged from 25 to 77.9 years according to the major LNs subtypes.
Overall in both sexes, the top five most frequent entities were: plasma
cell neoplasm (820), chronic lymphocytic leukemia/small lymphocytic
lymphoma (751), diffuse large B-cell lymphoma (733), follicular lym-
phoma (441) and marginal lymphoma (339). The LNs crude rate (CR)
was 33.4 and ASRE was 37.1 (95% confidence interval (CI): 36.0; 38.2),
45.7 (95% CI: 43.9; 47.6) in men and 29.7 (95% CI: 28.4; 31.1) in
women. There was a marked male predominance; the incidence sex
ratio (male/female) ranged from 1.1 for follicular and marginal lym-
phomas to 6.9 for hairy cell leukemia.
During 1996–2015, no statistically significant variations in in-
cidence trends were found for LNs [annual percentage change (APC):
0.1 (95% CI: −0.6; 0.8)], nor for broader lymphoma categories
(Table 2). Only the LNs NOS subtype category decreased, evidencing
the improved diagnostic specificity for these malignancies during the
last years.
According to our predictions, 17,950 new cases of LNs will be di-
agnosed in Spain in 2020, of which 1264 cases will be Hodgkin lym-
phoma, 738 precursor lymphoid neoplasms, 14,361 mature B-cell
neoplasms (i.e. 3248 chronic lymphocytic leukemia/small lymphocytic
lymphoma, 445 mantle cell lymphoma, 544 lymphoplasmacytic lym-
phoma/Waldenström's macroglobulinemia, 3025 diffuse large B-cell
lymphoma, 221 Burkitt lymphoma/leukemia, 1394 marginal lym-
phoma, 1811 follicular lymphoma, 129 hairy cell leukemia, and 3531
plasma cell neoplasms), 1067 mature T-cell and NK-cell neoplasms and
521 LNs NOS (data not shown).
4. Discussion
This paper presents epidemiological data of LNs in the province of
Girona (Spain) during a 20-year period. Incidence rates for the most
frequent subtypes were in accordance with those reported in France
(1980–2009) [2], United Kingdom (2004–2014) [3], Europe









































































































































































Trends in lymphoid neoplasms incidence rates by major subtypes in Girona,
Spain (1996–2015).
Period APC CI 95%
Lymphoid neoplasms 1996-2015 0.1 (-0.6; 0.8)
Hodgkin lymphoma 1996-2015 0.7 (-1.4; 2.9)
Precursor lymphoid neoplasms 1996-2015 −1.5 (-4.1; 1.2)
Mature B-cell neoplasms 1996-2015 0.3 (-0.5; 1.2)
Chronic lymphocytic leukemia/small
lymphocytic lymphoma
1996-2015 −0.1 (-1.4; 1.3)
Mantle cell lymphoma 1996-2015 1.8 (-2.8; 6.6)
Lymphoplasmacytic lymphoma/
Waldenström’s macroglobulinemia
1996-2015 1.2 (-1.3; 3.9)
Diffuse large B-cell lymphoma 1996-2015 0.5 (-1.1; 2.0)
Burkitt lymphoma/leukemia 1996-2015 −3.3 (-7.9; 1.6)
Marginal lymphoma 1996-2015 0.4 (-0.9; 1.7)
Follicular lymphoma 1996-2015 1.2 (-1.2; 3.6)
Plasma cell neoplasms 1996-2015 0.3 (-1.4; 1.9)
Mature T-cell and NK-cell neoplasmns 1996-2015 1.7 (-1.9; 5.6)
Lymphoid neoplasms, NOS 1996-2015 −7.4* (-11.2; -3.3)
APC, annual percent change; NOS, not otherwise specified.
Calculated only for major lymphoma categories and most incident mature B-cell
neoplasms.
* p-value<0.05.
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United States (projected incidence in 2016) [5] or Australia
(1982–2006) [6]. Regarding specific entities, we reported higher rates
of mantel cell lymphoma (ASRE=0.92), to the date only linked to few
genetic and environmental risk factors (i.e. atopy, allergy or farm life)
[7], which merit further research. In the same vein, Burkitt lymphoma/
leukemia incidence (ASRE=0.47) was particularly high in our region,
a pattern largely reported in other Southern European regions, yet
unexplained by well-stablished etiological factors [8]. Similarly, we
reported higher rates of chronic lymphocytic leukemia/small lympho-
cytic lymphoma (ASRE=6.62), mainly attributable to a higher com-
pleteness of our cancer registry for this entity rather than to a real peak
of incidence in our region. Chronic lymphocytic leukemia – as well as
Waldenström's macroglobulinemia – have been shown to be under-
reported by cancer registries given that they are prone to be indolent
and their diagnosis is not based on tissue pathology [9]. To ensure a
complete coverage of all chronic lymphocytic leukemia cases in our
region, we recently performed review of alternative sources of in-
formation (e.g. flow cytometry and hematologists databases) and evi-
denced a 18.2% of underreported cases during 1998–2013 [10]. Non-
specialized cancer registries thus, should make additional efforts to
ensure the surveillance of these malignancies is entirely accurate.
Incidence trends are broadly consistent with those reported for
other Western countries, which describe a steady increase in the in-
cidence of LNs during the 80′s and a stabilization in the late 90′s
[5,6,11]. Furthermore, in the United States, even a slight decline in
incidence rates by 2000 has been reported [5], which has been widely
related to a decrease in AIDS incidence, but also suggested to reflect
coding changes in 2001, when the WHO classification system was first
published [12]. Despite concordance between ICD-O-3, which in-
corporates the WHO Classification, and cases originally diagnosed and
coded under previous systems is generally high [13], several changes
can be rarely overcame. For example, the 2008 International Workshop
on chronic lymphocytic leukemia, changed the definition of the disease
by requiring an absolute B-cell count of 5000 cells/μL rather than the
previous absolute lymphocyte count of 5000 cells/μL, causing many
former Rai stage 0 cases to be reclassified as monoclonal B-cell lym-
phocytosis, a pre-malignant disorder not recorded by cancer registries
[14]. Overall, our results have to be interpreted cautiously since the
numerous changes in the classification of LNs over time could result in
errors of diagnosis or coding translation, particularly during the earlier
period.
The number of expected lymphoma cases depicts accurately the
cancer burden of LNs in Spain, which lacks of a cancer registry with
national coverage, but data on specific subtypes should be interpreted
with caution. Some WHO LNs subtypes are extremely rare, making
estimates less robust. However, overall, these results are interesting for
clinicians and public health in evaluating the cost of management and
new treatments for these pathologies.
In 2016, a new WHO manual was released [15] but the available
surveillance data are through 1996–2015 and do not reflect these up-
dates. The capability of registries to recode previous cases to these new
schemes will be limited because many require additional molecular or
clinical data [5]. However, changes to the 2008 classification are re-
latively small and would not be expected to change our conclusions.
The impact of these changes will be unclear until next years, when they
become adopted by pathologists and new entities routinely dis-
tinguished in clinical practice.
5. Conclusions
In conclusion, this study describes in detail the incidence of LNs
categorized by 2008 WHO subtype in a large population-based cohort.
This has not been performed previously for Spain, and complements the
subtype-specific analyses published for Europe [2–4], the United States
[5], and Australia [6]. This ‘real-world’ data will provide valuable
information to better inform etiological hypotheses and plan future
health-care services.
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